43 filings
8-K
Audentes Therapeutics, Inc.
15 Jan 20
Astellas Completes Acquisition of Audentes Therapeutics
10:03am
8-K
Audentes Therapeutics, Inc.
16 Dec 19
Departure of Directors or Certain Officers
6:51am
8-K
Audentes Therapeutics, Inc.
3 Dec 19
Astellas Enters into Definitive Agreement to
12:00am
8-K
Audentes Therapeutics, Inc.
7 Nov 19
Results of Operations and Financial Condition
4:06pm
8-K
Audentes Therapeutics, Inc.
8 Oct 19
Other Events
9:54pm
8-K
ljmnw2mogv 811
6 Aug 19
Results of Operations and Financial Condition
4:06pm
8-K
n818j3fr
28 Jun 19
Departure of Directors or Certain Officers
4:00pm
8-K
egopheo22a
7 Jun 19
Departure of Directors or Certain Officers
4:30pm
8-K
hb5ls5o
29 May 19
Departure of Directors or Certain Officers
4:02pm
8-K
rvdncf tp
7 May 19
Results of Operations and Financial Condition
4:03pm
8-K
g2hm1 szo
1 May 19
New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2
2:15pm
8-K
z90dxbds
8 Apr 19
Other Events
7:11am
8-K
xj9l9
27 Feb 19
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
12:00am
8-K
g3y15mrnq3rzciscfo
6 Nov 18
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
76g 8cdkc
11 Oct 18
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
4:24pm
8-K
mse0iz7 89
5 Oct 18
Regulation FD Disclosure
8:05am
8-K
j0kt fsedp9dyyia4
7 Aug 18
Results of Operations and Financial Condition
6:05am
8-K
cwqq2bhungwqg
8 Jun 18
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
r9kacz
16 May 18
Significant improvements in neuromuscular and respiratory function at 24-week timepoint
11:31am
8-K
7dy2o
9 May 18
Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
4:16pm